Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Generic Vancomycin in U.S. Appears to have Minimal Impact
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.
Analyst, Alan Carr, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Alan Carr, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
